Multi-institutional Analysis of 200 COVID-19 Patients Treated With Extracorporeal Membrane Oxygenation: Outcomes and Trends
MD Jeffrey P Jacobs, MSA, CCP (Emeritus Alfred H Stammers, MD James D St Louis, J W Awori Hayanga, MD Michael S Firstenberg, CCP (Emeritus Linda B Mongero, PhD Eric A Tesdahl, MD Keshava Rajagopal, PhD Faisal H Cheema, MD Kirti Patel, CCP Tom Coley, CCP Anthony K Sestokas, PhD Marvin J Slepian, MD Vinay Badhwar
The Annals of Thoracic Surgery, doi:10.1016/j.athoracsur.2021.06.026
BACKGROUND The role of extracorporeal membrane oxygenation (ECMO) in the management of patients with COVID-19 continues to evolve. The purpose of this analysis is to review our multi-institutional clinical experience involving 200 consecutive patients at 29 hospitals with confirmed COVID-19 supported with ECMO. METHODS This analysis includes our first 200 COVID-19 patients with complete data who were supported with and separated from ECMO. These patients were cannulated between March 17 and December 1, 2020. Differences by mortality group were assessed using c 2 tests for categoric variables and Kruskal-Wallis rank sum tests and Welch's analysis of variance for continuous variables.
RESULTS Median ECMO time was 15 days (interquartile range, 9 to 28). All 200 patients have separated from ECMO: 90 patients (45%) survived and 110 patients (55%) died. Survival with venovenous ECMO was 87 of 188 patients (46.3%), whereas survival with venoarterial ECMO was 3 of 12 patients (25%). Of 90 survivors, 77 have been discharged from the hospital and 13 remain hospitalized at the ECMO-providing hospital. Survivors had lower median age (47 versus 56 years, P < .001) and shorter median time from diagnosis to ECMO cannulation (8 versus 12 days, P [ .003). For the 90 survivors, adjunctive therapies on ECMO included intravenous steroids (64), remdesivir (49), convalescent plasma (43), anti-interleukin-6 receptor blockers (39), prostaglandin (33), and hydroxychloroquine (22). CONCLUSIONS Extracorporeal membrane oxygenation facilitates survival of select critically ill patients with COVID-19. Survivors tend to be younger and have a shorter duration from diagnosis to cannulation. Substantial variation exists in drug treatment of COVID-19, but ECMO offers a reasonable rescue strategy.
References
Barbaro, Maclaren, Boonstra, Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry, Lancet
Bartlett, Ogino, Brodie, Initial ELSO guidance document: ECMO for COVID-19 patients with severe cardiopulmonary failure, ASAIO J
Clerkin, Fried, Raikhelkar, COVID-19 and cardiovascular disease, Circulation
Henry, COVID-19, ECMO, and lymphopenia: a word of caution, Lancet Respir Med
Jacobs, Falasa, Machuca, Extracorporeal membrane oxygenation for patients with refractory COVID-19: what do we know and what do we need to learn?
Jacobs, Stammers, Louis, Extracorporeal membrane oxygenation in the treatment of severe pulmonary and cardiac compromise 8 JACOBS ET AL ECMO AND COVID-19
Kon, Smith, Chang, Extracorporeal membrane oxygenation support in severe COVID-19, Ann Thorac Surg
Madjid, Safavi-Naeini, Solomon, Vardeny, Potential effects of coronaviruses on the cardiovascular system: a review, JAMA Cardiol
Rajagopal, Keller, Akhanti, Advanced pulmonary and cardiac support of COVID-19 patients: emerging recommendations from ASAIO-a "living working document, ASAIO J
Shih, Dimaio, Squiers, Venovenous extracorporeal membrane oxygenation for patients with refractory COVID-19: multicenter experience of referral hospitals in a large health care system
Yang, Yu, Xu, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir Med